Infutraze (Zinc Chloride, Potassium Iodide, Sodium Selenite, Copper Chloride Dihydrate, Manganese Chloride Tetr)

The active ingredients—zinc chloride, potassium iodide, sodium selenite, copper chloride dihydrate and manganese chloride tetrahydrate—are delivered directly into the bloodstream where they serve as cofactors for enzymes, support antioxidant defenses, participate in thyroid hormone synthesis and facilitate numerous metabolic pathways critical for cellular health.

The dose of Infutraze is individualized and set by the prescribing clinician based on the patient’s age, weight, clinical condition and laboratory trace‑element levels. No fixed regimen is provided; dosing decisions are made by qualified healthcare professionals.

Safety data for Infutraze in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Infutraze, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Infutraze offers a balanced combination of five essential trace elements in a single intravenous formulation, which can simplify compounding compared with using separate single‑element additives. Its EU‑origin manufacturing follows GMP standards, providing consistent quality and compatibility with standard parenteral nutrition admixtures.

Infutraze must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Infutraze is administered intravenously, typically added to a parenteral nutrition bag or infused separately according to the prescribing clinician’s instructions. Administration should follow aseptic technique and be compatible with the other components of the nutrition regimen.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, copper or selenium toxicity manifesting as hepatic or neurologic symptoms, and significant electrolyte disturbances. Patients should be monitored closely during and after infusion for any signs of adverse reactions.

Infutraze should be avoided in patients with known hypersensitivity to any of its components, in those with severe copper or selenium overload, and in individuals where the risk of trace‑element supplementation outweighs the clinical benefit, as determined by the treating physician.